Trust Size
$16M
Peak Price
$5500.00
Current Price
$2.21
Return
-77.9%
Price Journey
What Happened
SeaStar Medical develops a blood-purification device called the Selective Cytopheresis Device (SCD) for treating hyperinflammation in critically ill patients with acute kidney injury.
SeaStar Medical went public through a SPAC merger and trades under ICU. The company's SCD device is designed to reduce organ-damaging inflammation in ICU patients by filtering and modulating activated neutrophils in the blood. The company has received FDA breakthrough device designation but remains in clinical development with going concern warnings and a reverse stock split.
Timeline
2021-01-19
S-1 Registration Filed
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1831868
Total SEC Filings
506
State of Incorporation
CO
Last Filing Date
2026-02-13
Business Location
Tampa, FL
Trust/Asset Size
$16M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for SeaStar Medical Holding